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Abstract 
Background: The World Health Organization (WHO) recommendation of treating uncomplicated malaria during 
the second and third trimester of pregnancy with an artemisinin‑based combination therapy (ACT) has already been 
implemented by all sub‑Saharan African countries. However, there is limited knowledge on the effect of ACT on preg‑
nancy outcomes, and on newborn and infant’s health.
Methods: Pregnant women with malaria in four countries (Burkina Faso, Ghana, Malawi and Zambia) were treated 
with either artemether–lumefantrine (AL), amodiaquine–artesunate (ASAQ), mefloquine‑artesunate (MQAS), or dihy‑
droartemisinin–piperaquine (DHA–PQ); 3127 live new‑borns (822 in the AL, 775 in the ASAQ, 765 in the MQAS and 
765 in the DHAPQ arms) were followed‑up until their first birthday.
Results: Prevalence of placental malaria and low birth weight were 28.0% (738/2646) and 16.0% (480/2999), respec‑
tively, with no significant differences between treatment arms. No differences in congenital malformations (p = 0.35), 
perinatal mortality (p = 0.77), neonatal mortality (p = 0.21), and infant mortality (p = 0.96) were found.
Conclusions: Outcome of pregnancy and infant survival were similar between treatment arms indicating that any 
of the four artemisinin‑based combinations could be safely used during the second and third trimester of pregnancy 
without any adverse effect on the baby. Nevertheless, smaller safety differences between artemisinin‑based combina‑
tions cannot be excluded; country‑wide post‑marketing surveillance would be very helpful to confirm such findings.
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Background
Pregnant women are more vulnerable to malaria than 
non-pregnant women because of altered immunity. Each 
year, about 85 million pregnant women in sub-Saharan 
Africa (SSA) are at risk of Plasmodium falciparum infec-
tion [1, 2]. Plasmodium falciparum malaria in preg-
nancy (either asymptomatic or symptomatic) can result 
in serious adverse outcomes for both the mother and 
the infant; maternal anaemia and placental malaria may 
result in low birth weight (LBW), miscarriage, stillbirth 
and infant death [3–6]. Effective and safe anti-malarial 
treatments decrease the occurrence of such adverse out-
comes. The World Health Organization (WHO) recom-
mends the use of artemisinin-based combination therapy 
(ACT) for the treatment of P. falciparum uncomplicated 
malaria during the second and third trimester of preg-
nancy [7]. All sub-Saharan African countries have already 
adopted and implemented such recommendation. 
Open Access
Malaria Journal
*Correspondence:  udalessandro@mrc.gm 
9 Medical Research Council Unit, The Gambia at the London School 
of Hygiene and Tropical Medicine, Fajara, Gambia
Full list of author information is available at the end of the article
Page 2 of 8Nambozi et al. Malar J          (2019) 18:105 
However, there is limited knowledge on the effect of ACT 
use on pregnancy outcomes and infant’s safety. Most of 
the available information originates from South-East 
Asia while there is little information from sub-Saharan 
Africa [8–11]. None of the studies in South-East Asia 
found evidence of fetal or maternal toxicity associated 
with artemisinin derivatives or ACT, with rate of abor-
tion, congenital abnormalities, and stillbirths within nor-
mal community ranges [9–11].
The results of the safety and efficacy of four arte-
misinin-based combinations, namely artemether-
lumefantrine (AL), amodiaquine-artesunate (ASAQ), 
mefloquine-artesunate (MQAS), dihydroartemisinin–
piperaquine (DHA–PQ), in African pregnant women 
with malaria were recently reported [12, 13]. AL had the 
best tolerability profile, acceptable cure rates, but the 
shortest post-treatment prophylaxis, while DHA–PQ 
seemed the most suitable treatment in terms of safety and 
efficacy, including its longer post-treatment prophylaxis 
[12, 13]. Here, the effect of the four artemisinin-based 
combinations on pregnancy outcome, and on neonatal 
and infant morbidity and mortality are reported.
Methods
The study was an open label, randomized controlled 
clinical trial comparing the efficacy and safety of four 
artemisinin-based combinations in pregnant women 
with P. falciparum uncomplicated malaria in the second 
and third trimester of pregnancy. The trial protocol has 
been reported in detail elsewhere (NCT00852423) [14]. 
Briefly, the trial was carried out between June 2010 and 
April 2015 at seven sites across four countries, namely 
Burkina Faso, Ghana, Malawi and Zambia. Pregnant 
women in their second or third trimester were enrolled 
and randomized to one of four treatment arms (AL, 
ASAQ, MQAS and DHAPQ). Participants were followed 
up until day 63 and then were seen at delivery.
Infant follow‑up
Mothers were asked to attend study health facilities with 
their babies at 4–6 weeks post-delivery and/or at the time 
of due vaccinations, 6  months later and at around the 
baby’s first birthday. Infants were examined by a study 
nurse or doctor and their medical conditions, if any, man-
aged as appropriate, including hospital admissions. Only 
congenital anomalies or birth defects and deaths were 
reported as serious adverse events (SAEs), and relevant 
information was collected by interviewing the mother 
and/or from hospital records. SAEs were codified using 
Medical Dictionary for Regulatory Activities (MeDRA) 
preferred term.
Perinatal mortality rate was defined as the number of 
perinatal deaths (stillbirths and early neonatal deaths) 
per 1000 total births [15]. Stillbirth was defined as a baby 
born dead after 24 weeks of gestation while miscarriage 
was defined as loss of the fetus at 24 weeks of gestation or 
earlier. Neonatal mortality rate was defined as the num-
ber of neonatal deaths (death during the first 28 days of 
life) per 1000 live births (first week of life: early neonatal 
death; 8–28 days of life: late neonatal death) [16]. Infant 
mortality rate was defined as the number of infant deaths 
(< 1  year of age) per 1000 live births. Placental malaria 
was classified as acute and chronic infection (presence 
of parasites with or without malaria pigment), past infec-
tion (presence of malaria pigment) and no infection (no 
parasites or malaria pigment).
The trial was approved by the ethics committee of 
the Antwerp University Hospital, Belgium, the relevant 
national or local ethics committees, and the national 
drug regulatory authorities of the four African participat-
ing countries.
Statistical analysis
The data analysis was based on an intention-to-treat 
(ITT) analysis, i.e. all infants born to mothers included 
in the study and randomized to one of the four treat-
ments were included, regardless of the number of doses 
taken. Nevertheless, denominator of percentages varied 
according to the availability of information; this explains 
the variation of denominator by variable. Twins were 
excluded from the analysis as mortality is higher in this 
group [17]. Descriptive statistics were used to summa-
rise socio-demographic and clinical characteristics of 
the mothers and infants. The difference between the 
treatment arms was calculated using logistic regres-
sion with fixed effects for treatment and country. The 
same approach was applied for the incidence of fever 
and other symptoms such as cough, diarrhoea, and dif-
ficulty in feeding at 4–6 weeks of life per 1000 live births. 
Continuous variables were compared between treatment 
groups using ordinary least square regression adjusted 
for country.
Incidence of SAEs in infants between treatment groups 
was compared by using a logistic regression model with 
fixed effects for treatment and country, to correct for 
possible imbalances in the reporting between countries.
Population-attributable fraction was used to assess 
the effect of placental malaria on LBW. The prevalence 
ratio (Pr) was set as the proportion of infected placentas 
(acute and chronic infections) with LBW divided by the 
proportion of uninfected placenta (past infections and 
uninfected) with LBW. The infected attributable frac-
tion was calculated as the percentage of infected placenta 
with LBW that was due to malaria [(Pr − 1)/Pr] while the 
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population-attributable fraction was the percentage of 
LBW cases that were due to malaria infection [18].
Infant mortality and hospital admissions rates were 
calculated as number of subjects with the event over 
the time at risk. The rate was compared between treat-
ment arms using Poisson regression or negative binomial 
regression model [19] adjusted for covariates: country, 
treatment, maternal age, delivery (gestational age, Hb, 
parasite density, baby Hb), birth weight, birth asphyxia, 
mode of delivery, congenital malformation, gravidity, pla-
cental malaria, place of delivery, ITN use by mother or 
baby, intermittent preventive treatment (IPTp) use, hos-
pital admission, malaria infection in new-born. In the 
univariate analysis, covariates were selected for inclu-
sion in multivariable model if the p-value was ≤ 0.25. In 
the final model covariates with a p-value of > 0.2 were 
dropped step by step. Stata v14 (Stata Corp, USA) was 
used for all statistical analyses. The significant level was 
set at p ≤ 0.05.
Results
A total 3258 out of the 3428 mothers enrolled had a 
recorded delivery outcome. Maternal characteristics such 
as gestational age (estimated by the total Ballard score), 
and maternal malaria infection status at delivery were 
not significantly different between treatment groups 
(Table  1). Fifty-two mothers delivered twins and were 
excluded from analysis. Out of the total recorded delivery 
outcomes, 3127 mothers (excluding mothers with twins) 
delivered live babies: 822 in the AL, 775 in the ASAQ, 765 
in the MQAS and 765 in the DHAPQ arms. There was 
no difference in the proportion of live births, adjusted for 
country, between treatment groups (p = 0.85) (Table  2). 
There were 13 (0.39%) miscarriages and 78 (2.36%) still-
births [12]. Among all live births, 118/3127 (3.8%) were 
lost during the 1-year follow-up while 6 mothers (0.2%) 
withdrew their consent.
Prevalence of LBW was 16.0% (480/2999), and was sig-
nificantly more frequent among women with acute and 
chronic placenta malaria (21.0%, 152/723) than in those 
with past or no infection (13.7%, 259/1892) (p < 0.01). 
Nevertheless, LBW (p = 0.54) and mean birth weight 
were similar between treatment arms (Table  2). Preva-
lence of both cord blood anaemia and congenital malaria 
infection (malaria parasites in cord blood) was low and 
not significantly different between treatment arms. Simi-
larly, there were few congenital abnormalities identified 
at birth (1.4%, 44/3065), with no statistically significant 
difference between study arms (Table 2) [12].
Table 1 Gestational age and maternal malaria infection status at delivery
a Adjusted by country
b The proportion of current (acute and chronic) and past infection vs. no infection, adjusted for country, p = 0.47. Proportion of acute and chronic infection vs. past or 
no infection, adjusted for country p = 0.52
c One woman randomized to the ASAQ group was treated with MQAS; in the safety analysis this woman was included in the MQAS group
AL ASAQ MQAS DHAPQ p-valuea
N N N N
Maternal age median (IQR) 881 21 (18–26) 842c 22 (19–27) 850c 22 (19–27) 855 20 (18–25) 0.67
Gestational age (week) median (IQR) 804 38 (36–38) 729 38 (38–40) 733 38 (36–40) 709 38 (36–38) 0.30
Gravidity n (%) 880 842 850 855 0.55
 1st pregnancy 319 (36.3) 315 (37.4) 278 (32.7) 343 (40.1)
 2nd pregnancy 204 (23.2) 187 (22.2) 201 (23.7) 216 (25.3)
 3rd or more 357 (40.6) 340 (40.4) 371 (43.7) 296 (34.6)
Malaria prevalence (peripheral blood) 
n (%)
829 120 (14.5) 756 95 (12.6) 752 123 (16.4) 748 75 (10.0) 0.21
Parasite density; median (IQR) 120 1560 (440–6804) 95 1800 (320–8220) 123 1729 (561–9000) 75 2320 (480–8960) 0.09
 % ≤ 2000/µL (n) 55.0 (66) 53.7 (51) 52.0 (64) 46.7 (35)
 % > 2000/µL (n) 45.0 (54) 46.3 (44) 48.0 (59) 53.3 (40)
Gametocyte carriage n (%) 829 3 (0.4) 756 4 (0.5) 752 4 (0.5) 748 2 (0.3) 0.89
Maternal Hb median (IQR) 828 11.2 (10.1–12.2) 757 11.5 (10.4–12.4) 752 11.3 (10.3–12.3) 749 11.2 (10.3–12.2) 0.30
Placenta Malaria n (%)b 711 655 674 664
 Acute infection 7 (1.0) 14 (2.1) 13 (1.9) 11 (1.7)
 Chronic infection 191 (26.9) 168 (25.6) 177 (26.3) 171 (25.8)
 Past infection 444 (62.4) 382 (58.3) 398 (59.1) 409 (61.6)
 No infection 69 (9.7) 91 (13.9) 86 (12.8) 73 (11.0)
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The overall prevalence of acute and chronic placental 
malaria was 28.0% (738/2646). Attributable fraction anal-
ysis suggests placenta malaria (acute and chronic) was 
responsible for 35% of the LBW among women with pla-
cental malaria infection (infected attributable fraction). 
At the prevalence found in this trial, the percentage of all 
LBW babies due to malaria (population-attributable frac-
tion) was estimated at 13% (Table 3).
Besides congenital abnormalities (almost half of them 
(46%, 23/50) polydactyly), the most commonly reported 
SAEs among infants were infections and infestations 
(Table  4), the most frequent being pneumonia (26.1%, 
12/46), neonatal sepsis (21.7%, 10/46), sepsis (17.4%, 
8/46), and malaria (8.7%, 4/46), with no statistically sig-
nificant difference between treatment arms.
Reported hospital admissions (episodes per 1000 live 
birth/year) were similar between treatment arms: AL: 90, 
ASAQ: 104, MQAS: 56, DHAPQ: 85 (p = 0.91) (Table 5).
During the 1-year follow up, when adjusting for coun-
try and other potential risk factors, babies born at home 
(IRR 1.44, 95% CI 1.02–2.03) (p = 0.04) or with a congeni-
tal abnormality (IRR 5.12, 95% CI 2.09–12.51) were more 
likely to be admitted in hospital. Infants sleeping under 
bed nets (0.36, 95% CI 0.21–0.62) (p < 0.01) were less 
likely to be admitted in hospital than those who were not 
(Table 6).
There were 70 deaths within the first month of life, 
representing 59.3% (70/118) of all infant deaths, with no 
difference between study arms (55.2% in AL, 74.1% in 
ASAQ, 41.7% in MQAS and 63.2% in DHAPQ) (p = 0.47). 
The large majority of neonatal deaths (71.4%, 50/70) 
occurred in the first week of life, at the mean age of 1.3 
(SD 1.9) days, with no statistically significant difference 
between treatment arms (AL: 2.1; ASAQ: 1.5; MQAS: 0.3; 
DHAPQ: 1.0) (p = 0.19). Neonatal mortality (early and 
late) rate was 22.4 deaths per 1000 live births (AL: 19.5; 
ASAQ: 25.8, MQAS: 13.1; and DHAPQ: 31.4) (p = 0.21); 
perinatal mortality rate was 21.9 deaths per 1000 total 
births (AL: 17.9; ASAQ: 17.7, MQAS: 28.0; and DHAPQ: 
24.2) (p = 0.77), with no significant difference between 
the treatment groups (Table  7). The overall infant mor-
tality rate was 41.0/1000 live births per year, and similar 
between treatment arms (AL: 38.7, ASAQ: 38.0, MQAS: 
33.4 and DHAPQ: 54.1) (p = 0.96) (Table  5). Infant 
Table 2 Baseline characteristics of study infants at delivery (%)
a Adjusted by country
b Reported as SAE at delivery
c Calculated by Ballard score
d Cord blood at 14 g/dL cut off for congenital anaemia and cord blood for malaria
AL ASAQ MQAS DHAPQ p-valuea
N Value N Value N Value N Value
Live births by country 0.85
 Burkina Faso 280 278 (99.3) 279 278 (99.6) 275 268 (97.5)
 Ghana 245 235 (95.9) 241 229 (95.0) 252 243 (96.4)
 Malawi 276 269 (97.5) 269 262 (97.4) 270 268 (99.3)
 Zambia 282 275 (97.5) 273 268 (98.2) 264 254 (96.2)
 Birth asphyxia 706 19 (2.7) 635 42 (6.6) 658 44 (6.7) 648 39 (6.0) 0.91
 Congenital  abnormalityb 815 17 (2.1) 757 12 (1.6) 751 12 (1.6) 742 6 (0.8) 0.35
 Prematurityc 838 78 (9.3) 793 25 (3.2) 789 57 (7.2) 786 70 (8.9) 0.65
 Congenital  malariad 808 7 (0.9) 727 2 (0.3) 719 1 (0.1) 711 1 (0.1) 0.15
 Anaemia at  birthd 793 12 (1.5) 720 7 (1.0) 713 10 (1.4) 696 10 (1.4) 0.36
 Birth weight mean (SD) 804 2856 (452) 742 2873 (463) 733 2860 (460) 720 2889 (463) 0.56
 LBW < 2500 g 804 138 (17.2) 742 118 (15.9) 733 119 (16.2) 720 105 (14.6) 0.54
Table 3 Risk of LBW associated with placental malaria
The prevalence ratio (Pr) is the proportion of infected women with LBW divided by the proportion of uninfected women with LBW. The infected attributable fraction 
is the percentage of infected women with LBW that is due to malaria [(Pr − 1)/pr]. The population-attributable fraction is the percentage of LBW cases that are due to 
malaria infection: [PM(Pr − 1)]/{1 + [PM(Pr − 1)]} where PM is the proportion with placental malaria infection
Placenta malaria 
prevalence
Prevalence of LBW Prevalence ratio Infected attributable fraction Population-
attributable 
fractionPlacenta malaria No Placenta malaria
27.89 (738/2646) 21.0 (152/723) 13.7 (259/1892) 1.535 34.87 12.99
Page 5 of 8Nambozi et al. Malar J          (2019) 18:105 
mortality was significantly higher in Zambia than in Bur-
kina Faso but not in Ghana or Malawi (Table 6).
When adjusting by country and other potential risk 
factors, LBW babies had an almost 2-fold higher risk of 
dying during the first year of life than other babies (IRR 
1.78, 95% CI 1.03–3.06, p = 0.04). Babies born with birth 
asphyxia (IRR 10.89, 95% CI 4.48–26.46) (p < 0.01) and 
congenital abnormality (25.47, 95% CI 10.46–62.02) 
(p < 0.01) had significantly higher risk of dying than other 
infants (Table 6).
Discussion
The PREGACT study aimed at evaluating the safety and 
efficacy of four artemisinin-based combinations when 
administered to pregnant women with malaria [12]. 
The follow-up included also the offspring’s first year 
of life to identify any potential problem the treatment 
may have. Results are reassuring as no significant differ-
ences between study arms in terms of reported illness, 
hospital admissions or infant mortality were found. It is 
extremely difficult to estimate cause-specific mortality 
as most infant deaths occurred outside a health facility 
[20–23]. Some of the most frequent SAEs reported in 
this study, namely neonatal sepsis, respiratory infections 
and malaria, are also among the most common causes 
of infant deaths in malaria-endemic African countries, 
where infant mortality rates are the highest in the world 
[19, 20], and were probably among the most frequent 
cause of infant death.
More than two-third of all neonatal deaths occurred in 
the first week of life. In this age group, malaria is usually 
an indirect cause of death as it causes LBW which in turn 
increases the risk of dying in the first year of life [20, 24]. 
This is confirmed by the significant association between 
LBW and placenta malaria (acute and chronic) and the 
substantially higher mortality in LBW babies. Few tri-
als have evaluated the effect of chemoprevention during 
pregnancy on miscarriages, stillbirths, perinatal deaths, 
neonatal or infant deaths, and usually these studies are 
underpowered to detect clinically important differences 
[25] or do not follow infants until their first birthday 
[26, 27]. Such a difference may be found when compar-
ing an intervention to a placebo arm, as in Mozambique 
where IPTp with sulfadoxine–pyrimethamine (SP) was 
compared to a placebo arm [28]. Indeed, in this trial sig-
nificantly fewer neonatal deaths, particularly early infant 
deaths, occurred in the intervention than in placebo 
group despite no difference in prevalence of anaemia, 
LBW or placenta malaria (active and past infection) [28]. 
However, infant mortality did not differ between study 
arms although among the 58 infant deaths reported, 
more than half occurred in the placebo arm [20]. When 
all women included in a trial receive a malaria-preventive 
Table 4 SAEs in infants by treatment arm
SAE by system organ class AL (N = 822) ASAQ (N = 775) MQAS (N = 765) DHAPQ 
(N = 765)
% n % n % n % n
Congenital disorders 2.1 17 1.5 12 1.6 12 0.8 6
Infection and infestations 1.5 12 1.5 12 0.9 7 2.0 15
Respiratory disorders 1.0 8 0.8 6 0.9 7 1.0 8
General disorders 0.6 5 0.4 3 0.8 6 1.0 8
Gastrointestinal disorders 0.4 3 0.0 0 0.3 2 0.0 0
Perinatal complications 0.4 3 0.5 4 0.1 1 0.9 7
Blood disorders 0.2 2 0.0 0 0.1 1 0.1 1
Hepatobiliary disorders 0.1 1 0.0 0 0.0 0 0.0 0
Metabolism and nutrition disorders 0.1 1 0.1 1 0.0 0 0.3 2
Reproductive and breast disorders (e.g. labia 
enlarged)
0.1 1 0.0 0 0.0 0 0.0 0
Nervous system disorders 0.0 0 0.1 1 0.1 1 0.1 1
Table 5 Incidence of hospital admissions, infant mortality
IRR incidence rate ratio
Variable N/PYAR IR IRR (95% CI) p-value
Hospital admissions
 AL 67/748.6 0.09 Reference
 ASAQ 74/710.6 0.10 1.01 (0.71–1.43)
 MQAS 40/718.4 0.06 0.88 (0.57–1.35)
 DHAPQ 60/702.9 0.09 1.01 (0.70–1.47) 0.91
Infant mortality
 AL 29/748.6 0.04 Reference
 ASAQ 27/710.6 0.04 0.96 (0.44–2.09)
 MQAS 24/718.4 0.03 0.94 (0.47–1.86)
 DHAPQ 38/702.9 0.05 1.12 (0.57–2.20) 0.96
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intervention, significant differences in neonatal and/or 
infant mortality are unlikely to be found unless one of the 
interventions has either a negative or positive effect on 
infant survival. For example, a trial comparing IPTp with 
either SP (IPTp-SP) or mefloquine (MQ) did not report 
any difference in neonatal and infant mortality between 
the two arms as both treatments are efficacious against 
malaria [29]. Therefore, the similar outcomes in the four 
arms of our trial are not surprising as all treatments were 
extremely efficacious against malaria [12]. A difference 
may have occurred if any of the treatments tested would 
have had an adverse effect on the fetus or infant survival 
or if the four tested artemisinin-based combinations were 
compared to a non-ACT. Indeed, in Uganda spontaneous 
abortions and neonatal deaths were less frequent among 
women treated with AL than in those treated with qui-
nine although the difference was not statistically signifi-
cant [30]. In Mali, the proportion of stillbirths (4.8%) and 
neonatal deaths (2.9%) after 2-dose IPTp-SP were similar 
to those observed in this trial (2.36% and 2.24%, respec-
tively), confirming the safety of the ACT when given dur-
ing the 2nd or 3rd trimester of pregnancy [31]. The early 
concerns about an increased risk of stillbirth associated 
with mefloquine [32] were not confirmed subsequently 
by other studies on mefloquine alone or combined with 
artesunate [33–35]; birth defects and fetal loss rates were 
similar to background rates [36] or to other antimalarial 
treatments [12, 37].
Placenta sequestration of malaria parasites can lead to 
inflammatory response, particularly in first-time moth-
ers who often have high density infections, and also affect 
development of the fetal circulation. This decreases the 
supply of nutrients and oxygen to the fetus, resulting in 
intrauterine growth retardation and LBW, which is a risk 
factor for higher infant mortality [38]. More than a quar-
ter of women had an active placenta infection, mainly 
chronic ones, i.e. with both parasites and malaria pig-
ment, while evidence of past (non-active) infection was 
found in more than 60% of women. As the trial recruited 
Table 6 Risks (incidence rate ratio) of  infant mortality 
and hospital admission in PREGACT study
IRR incidence rate ratio
IRR 95% CI p-value
Infant mortality
 AL 1 – 0.96
 ASAQ 0.96 0.44–2.09
 MQAS 0.94 0.47–1.86
 DHAPQ 1.12 0.57–2.20
 Congenital anaemia 2.93 0.96–8.96 0.06
 Low birth weight 1.78 1.03–3.06 0.04
 Birth asphyxia 10.89 4.48–26.46 < 0.01
 Congenital abnormality 25.47 10.46–62.02 < 0.01
 Burkina Faso 1 – < 0.01
 Ghana 1.02 0.31–3.36
 Malawi 2.14 0.89–5.15
 Zambia 4.02 1.85–8.73
Hospital admission
 AL 1 – 0.91
 ASAQ 1.01 0.71–1.43
 MQAS 0.88 0.57–1.35
 DHAPQ 1.01 0.70–1.47
 Baby ITN use 0.36 0.21–0.62 < 0.01
 Born at home 1.44 1.02–2.03 0.04
 Congenital malaria 3.80 0.93–15.56 0.06
 Congenital abnormality 5.12 2.09–12.51 < 0.01
 Burkina Faso 1 – < 0.01
 Ghana 1.02 0.68–1.54
 Malawi 1.89 1.33–2.69
 Zambia 0.49 0.31–0.79
Table 7 Perinatal and neonatal mortality, and morbidity during the first month of life by treatment (%)
a p-values are from logistic regression adjusted for country
b values are n (/1000 live births) except perinatal mortality which has n (/1000 total births)
AL ASAQ MQAS DHAPQ p-valuea
N Valueb N Valueb N Valueb N Valueb
Perinatal mortality 837 15 (17.9) 789 14 (17.7) 787 22 (28.0) 784 19 (24.2) 0.77
Neonatal mortality 822 16 (19.5) 775 20 (25.8) 765 10 (13.1) 765 24 (31.4) 0.21
Morbidity
 Fever (4–6 week) 764 37 (48.4) 718 34 (47.4) 715 42 (58.7) 680 23 (33.8) 0.82
 Diarrhoea (4–6 week) 764 14 (18.3) 717 22 (30.7) 715 19 (26.6) 679 4 (5.9) 0.62
 Cough (4–6 week) 764 34 (44.5) 717 33 (46.0) 715 56 (78.3) 679 52 (76.6) 0.02
 Difficulty in feeding (4–6 week) 764 2 (2.6) 717 5 (7.0) 715 6 (8.4) 679 1 (1.5) 0.76
 Jaundice (4–6 weeks) 764 0 (0.0) 717 1 (1.4) 714 2 (2.8) 679 1 (1.5) 0.90
 Other symptoms (4–6 week) 764 33 (43.2) 717 44 (61.4) 715 51 (71.3) 679 16 (23.6) 0.33
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pregnant women with malaria, such a high prevalence 
is understandable. In addition, women were actively fol-
lowed up during the 63  days post-treatment, and pas-
sively until delivery. Most women were treated during 
the second trimester and the early third trimester of 
pregnancy, and the treatment by itself could not prevent 
women to be re-infected near delivery. Indeed, longitudi-
nal genotyping of P. falciparum isolates during gestation 
in Cameroonian pregnant women showed that 77% of 
placental parasites were acquired from 30  weeks’ gesta-
tion onwards [38].
Fetal anaemia plays a role in neonatal survival [20, 39]. 
Cord blood anaemia was particularly low, just around 1% 
and similar in all treatment arms, although it increased 
the risk of infant death almost 3-fold, an association that 
was of borderline significance. Such low prevalence is 
surprising when considering that a recently published 
study on a trial assessing IPTp with either SP or MQ 
reported a prevalence of about 10%, with a definition of 
anaemia that was more conservative than in this study 
(Hb < 12.5 g/dl versus Hb < 14.0 g/dl) [29]. The reason for 
such difference is unclear.
The longer recall period between the post-partum vis-
its, at 4–6 weeks, and then at 6 and 12 months could have 
affected the accuracy of information on morbidity. Nev-
ertheless, it is unlikely the study team missed any infant 
death. Moreover, such recall bias would have equally 
affected the 4 study arms.
Conclusions
In summary, there were no major differences between 
treatment arms in terms of perinatal, neonatal and 
infant mortality, nor on the overall occurrence of SAEs 
in babies, indicating that any of the tested artemisinin-
based combinations can be used for the treatment of 
malaria during the second and third trimester of preg-
nancy without any adverse effect on the baby. As women 
were treated only once, repeated treatments may have 
resulted in a different outcome. It is reassuring that 
repeated administration of DHAPQ as IPTp did not 
increase the occurrence of adverse birth outcomes, indi-
cating that at least this ACT could be safely administered 
2–3 times during the second and third trimester of preg-
nancy [27]. Although the number of women treated and 
infants followed up is substantial, smaller safety differ-
ences between artemisinin-based combinations cannot 
be excluded. Country-wide post-marketing surveillance 
would be very helpful in confirming that any of the 4 
combinations tested can be safely used to treat malaria 
during pregnancy.
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